EMA Authorised: Quofenix (delafloxacin meglumine) — A. Menarini Industrie Farmaceutiche Riunite s.r.l.

View source ↗

Summary

EMA has authorised Quofenix, a delafloxacin meglumine antibacterial product, for the treatment of community-acquired infections. Decision date: 25 February 2025…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Infections

Drugs mentioned

• Quofenix (delafloxacin meglumine)

Snippet

Status: Authorised. Therapeutic area: Community-Acquired Infections. MAH: A. Menarini Industrie Farmaceutiche Riunite s.r.l.. Decision date: 25/02/2025